VARIABLE THICKNESS VASCULAR TREATMENT DEVICE SYSTEMS AND METHODS
A distal embolic protection device for dedicated use in cerebral arterial blood vessels is described. The distal embolic protection device comprises a variable-thickness micro-guidewire and a collapsible filtering device mounted on the microguidewire over two mobile attachment points so that in its collapsed configuration, the thickness of the microguidewire and the filtering device at this region is less than or equal to 0.017 inch (0.432 mm) in thickness to be able to pass through existing conventional microcatheters. The mobile attachment points allow for rotatory and longitudinal mobility of the microguidewire while the filtering device is stable thereby decreasing the risk of trauma to the fragile cerebral arterial blood vessels. Preferably, the filtering device comprises an expansion assembly, e.g., a plurality of struts attached to a filter membrane that are in a folded position which self expand to the desired dimensions within the cerebral blood vessels. Also described are methods of using the distal embolic protection devices of this invention.
The present application is a continuation of U.S. patent application Ser. No. 11/859,272, filed Sep. 21, 2007 and issued as U.S. Pat. No. 9,034,007 on May 19, 2015. Any and all applications for which a foreign or domestic priority claim is identified in the Application Data Sheet as filed with the present application are hereby incorporated by reference under 37 C.F.R. §1.57.
FIELD OF INVENTIONThis invention is related generally to the field of intravascular medical devices. Particularly a distal embolic protection device as well as methods for use of the device during neurovascular interventional procedures in the cerebral arterial blood vessels.
BACKGROUND OF INVENTIONStroke is the leading cause of long term disability in the United States and the second leading cause of death worldwide with over 4.4 million deaths in a year (1999).1 There are over 700,000 new strokes every year in the United States.2 Around 85% of all strokes are acute ischemic strokes caused from a blockage in a blood vessel or a blood clot occluding a blood vessel.2 In 1996, the FDA approved a thrombolytic drug to dissolve blood clots called recombinant tissue plasminogen activator (r-tpa).3 Despite practice guidelines from multiple national organizations stating the intravenous r-tpa is the standard of care for patients with acute ischemic stroke within 3 hours from symptom onset,3 only 3-4% of patients with acute ischemic stroke received this drug in the United States.4 Unlike intravenous r-tpa, Intra-arterial infusion of thrombolytic agents can be used for up to 6 hours from acute ischemic stroke symptom onset and could benefit more people.5 Currently, intra-arterial infusion of thrombolytic agents are administered to a blood clot and the blood clot breaks up into smaller blood clots and travel downstream and potentially close up smaller cerebral blood vessels. With advances in regional stroke networks, there are more and more stroke patients who are getting access to intra-arterial thrombolysis and therapies, and are as high as 21.6%.4 However, there is no currently available distal embolic protection device that is dedicated to the cerebral blood vessels.
More than 8% of all acute ischemic strokes are from blockages in the cervical or neck carotid artery.2 Studies have shown that performing percutaneous balloon angioplasty and stenting on these blockages result in emboli or debris being dislodged downstream and could cause further strokes and therefore there have been large clinical trials of angioplasty and stenting of the carotid artery in the neck with distal embolic protection devices being used.6 In addition to blockages in the neck region of the carotid artery, more than 8% of all acute ischemic strokes are due to blockages in the cerebral arterial blood vessels called intracranial stenosis.2 Recently there has been a new device approved for intracranial angioplasty and stenting.7 Although the risks of small emboli or debris being dislodged during intracranial angioplasty and stenting is similar to the cervical carotid artery and the rest of the body, there are no distal embolic protection devices in the market dedicated for cerebral arterial blood vessels. In addition, the distal embolic protection devices currently available for the cervical carotid artery are too bulky for use in the tortuous and fragile cerebral arterial blood vessels.
Embolic protection devices have been developed for the cervical carotid artery prior to carotid angioplasty and stenting.6 However, these devices do not have a small profile for use in the cerebral arterial blood vessels and will not be able to track and traverse the tortuous cerebral arterial blood vessels.
Barbut in U.S. Pat. No. 6,165,199 has described embolic protection devices that can be used for the cerebral arterial blood vessels. This is a proximal embolic protection device wherein the embolic protection device is before the clot or blockage comprising of a proximal balloon occlusion catheter to create flow arrest and an aspiration device to suction out the emboli or debris during the interventional procedure in the cervical and cerebral blood vessels. The drawbacks of a proximal protection device are that the flow arrest performed to decrease emboli or debris from traveling downstream can be detrimental in itself, since creating a flow arrest in an already ischemic blood vessel during the long neurovascular interventional procedures would in itself worsen the cerebral ischemia and worsen the strokes. Bose et al in U.S. Pat. No. 6,669,721 describe thin-film distal embolic protection devices that can be potentially used in the cerebral blood vessels. The device has one or two rings and a thin-film filter that is attached to the guidewire. The drawbacks of this device is that during neurovascular interventional procedures, there is constant exchange of microcatheters, balloon catheters, and stent catheters over the guidewire or microguidewire, and a distal embolic protection device that is rigidly fixed to the guidewire or microguidewire would cause trauma to the cerebral arterial blood vessel wall as there will not be any mobility of the wire independent of the distal embolic protection device. Hopkins et al in U.S. Pat. No. 6,544,279 B1 describe distal embolic protection devices that do have mobility over a guidewire or microguidewire, however these guidewires or microguidewires are of uniform thickness and the mobile attachment point in these devices extend through the entire length of the device. Current microguidewires used in neurovascular interventional procedures to perform intracranial angioplasty and stenting among other procedures use microguidewires in the thickness of 0.014 inch (0.356 mm).7 Current microcatheters used for intracranial cerebral blood vessel catheterization for stroke as well as during intracranial angioplasty and stenting have an inner diameter of about 0.017 inch (0.432 mm). Having a distal embolic protection device mounted on a uniform thickness microguidewire of a thickness of 0.014 inch (0.356 mm) will not permit the distal embolic protection device in the collapsed form to have a thin enough or small enough profile to be compatible with existing microcatheters that are 0.017 inch (0.432 mm) in inner diameter. Having a distal embolic protection device mounted on a uniform thickness microguidewire with a mobile attachment point that extends through the entire length of the device will increase the overall thickness of the device in the collapsed configuration thereby limiting the trackability of the device and inhibiting access to the tortuous and narrow cerebral arterial blood vessels.
BRIEF SUMMARY OF INVENTIONThe present invention provides a distal embolic protection device that can be used for neurovascular interventional procedures including, but not limited to, intra-arterial thrombolytic or clot dissolving drug infusion for acute ischemic stroke, as well as percutaneous transluminal intracranial balloon angioplasty and stenting procedures for patients at risk for stroke so that the small emboli or debris that are dislodged during these procedures can be retrieved safely. The distal embolic protection device of this invention has a thin and small profile such that they are compatible with existing standard microcatheters. The distal embolic protection device of this invention is not attached to a balloon or stent. The present invention also addresses the limitations of all the prior art on embolic protection devices discussed above as well as those that have been referenced.
An object of this invention is to have a distal embolic protection device that is dedicated to the cerebral arterial blood vessels and is suitable for use in cerebral arterial blood vessels of 1.5 mm to 4.5 mm in diameter. The definition of cerebral arterial blood vessels is described in the detailed description of
Another object of this invention is to have an embolic protection device that does not have to cause flow arrest to provide embolic protection. Devices that cause flow arrest have a risk of worsening a stroke. Therefore the embolic protection device of this invention is distal rather than proximal to the blockage or blood clot and not proximal to the blockage or blood clot.
Another object of this invention is to have a distal embolic protection device that can pass through the tortuous cerebral arterial blood vessels with no or little trauma to the vessels. Current embolic protection devices are transported or moved through catheters using a small stearable microwire. Due to the bulky nature of current embolic protection devices, it is very difficult to navigate through even in straight blood vessels leave alone tortuous blood vessels.
Another object of this invention is to have a distal embolic protection device comprising a collapsible filtering device that has a small thin profile so that in the collapsed configuration of the filtering device, the thickness of the distal embolic protection device is no more than about 0.017 inch (0.432 mm), preferably no more than about 0.014 inch (0.356 mm), and can be delivered and retrieved via a standard microcatheter (inner diameter of 0.017 inch, 0.432 mm), a balloon catheter or stent catheter that are used in neurovascular interventional procedures. The filtering device is not attached to a balloon or stent.
Another object of this invention is a distal embolic protection device comprising a variable thickness microguidewire and a collapsible filtering device, wherein the filtering device is rotatably mounted on the distal segment of the variable thickness microguidewire. The variable thickness microguidewire comprises a thinner segment bordered on both ends by thicker segments. The thinner segment is no more than about 0.010 inches in thickness and preferably about 0.008 to 0.010 inch (0.203 to 0.254 mm). The thicker segments, which make up the majority of the microguidewire, are thicker than the thinner segment and preferably no more than 0.017 inch (0.432 mm) in thickness, more preferably no more than about 0.014 inch (0.356 mm). The variable thickness microguidewire may comprise a core microguidewire that extends through the entire length, or a portion of, of the microguidewire and a coating or covering or flexible hypotube or a combination thereof over the core microguidewire. The filtering device is mounted on the thinner segment, which is in the distal segment of the microguidewire to maintain a small thin profile so that trackability is maintained as well as compatibility with existing microcatheters, balloon catheters and stent catheters that are used in neurovascular interventional procedures. Preferably the small thin profile is no more than about 0.017 inch (0.432 mm) and more preferably no more than about 0.014 inch (0.356 mm).
Another object of this invention is a distal embolic protection device comprising a variable thickness microguidewire and a filtering device, wherein the microguidewire and filtering device have rotational and longitudinal movement relative to and independently of each other, such that the filtering device can remain stable within the blood vessel while there is motion on the microguidewire both in the rotational as well as longitudinal directions relative to the filtering device so that there is no, or very limited, trauma to the fragile cerebral arterial blood vessels.
The filtering device of the distal embolic protection device of this invention may comprise mobile attachment points on its proximal and distal ends wherein the mobile attachment points attach the filtering device to the microguidewire. The mobile attachment points are of such a size that that the thickness of the filtering device in the collapsed configuration is smaller than a cerebral arterial blood vessel and can pass through standard microcatheters that are used in neurovascular interventional procedures. Preferably the attachment points in conjunction with the filtering device in the collapsed configuration are no more than about 0.017 in (0.432 mm), and more preferably not more than about 0.014 inch (0.356 mm) in thickness. Preferably the attachment points are short and abut, but do not cover, the thicker segments of the microguidewire.
In an embodiment of this invention, the distal embolic protection device comprises a filtering device rotatably mounted on the thinner segment of the microguidewire, and further comprises cylindrical coils that wind around the thinner segment of the microguidewire and connect the proximal and distal ends of the filtering device to the proximal and distal stops of the thicker segments of the microguidewire. The attached cylindrical coils decrease the shear stress on the thinner segment of the microguidewire during the retrieval of the distal embolic protection device.
Another object of this invention the distal embolic protection device comprises a radio-opaque portion that enables the device to be visualized during fluoroscopic neurovascular interventional procedures. For example, the thicker segments of the microguidewire, or the distal end of the microguidewire, or the filtering device itself may comprise radio-opaque sections so that the operator during a medical procedure can distinguish the filtering device and its position relative to the thicker and thinner segments of the microguidewire.
The distal embolic protection devices of this invention are dedicated to use in cerebral arterial blood vessels and their use in the treatment of existing stroke patients and patients that are at risk for strokes. The methods of this invention include e.g., crossing a vascular blockage or blood clot with a standard microcatheter and microwire. Then removing the microwire and once the microwire is removed, the distal embolic protection device is advanced via the microcatheter to the desired location. As the distal embolic protection device is not involved in navigation, it is able to pass the tortuous curves of the cerebral blood vessels due to the novel delivery system. The microguidewire is also designed to be compatible with existing microcatheters, balloon catheters and stent catheters used in neurovascular interventions. In addition, the stops in the distal part of the microguidewire and the mobile attachment points on the filtering device allow for mobility of the microguidewire both in the rotatory and longitudinal directions relative to the filtering device, wherein the filtering device is stable in the cerebral blood vessel thereby minimizing vessel trauma or dissections. The variable thickness of the distal part of the microguidewire also allows for the smaller overall profile of the device and improves its compatibility with existing microcatheters, balloon catheters, and stent catheters. The small profile also allows for easy retrieval of the distal embolic protection device of this invention using existing microcatheters, balloon catheters or stent catheters making the procedure shorter and safer.
The methods of this invention for collecting thrombo-embolic material, debris or clots released during percutaneous neurovascular interventional procedures specifically performed in the cerebral arterial blood vessels, comprises inserting the distal embolic protection device of this invention into a cerebral arterial blood vessel having an area of stenosis or a clot, deploying the filtering device distal to the area of blockage or clot and allowing the filtering device to expand to fill the diameter of the cerebral arterial blood vessel. The methods of this invention may further comprise advancing a standard microcatheter over a standard microwire across the area of stenosis or clot, positioning the microcatheter distal to the stenosis or clot, withdrawing the microwire, and advancing the distal embolic protection device through the standard microcatheter. The thickness of the thicker segments of the variable thickness microguidewire is no more than about 0.017 inch (0.432 mm) and preferably no more than about 0.014 inch (0.356 mm) such that it is compatible for use with standard microcatheters, which have an inner lumen diameter of about 0.017 inch (0.432 mm). In addition, the methods of this invention may further comprise withdrawing the microcatheter, while keeping the microguidewire in position distal to the stenosis or clot, unsheathing the distal embolic protection device and expanding the filtering device to the inside size of the cerebral arterial blood vessel, ranging from 1.5 mm to 4.5 mm, and wherein the expanded shape of the filter membrane is a hemispherical, helical or conical shape and spans the cerebral arterial blood vessel. The method may also comprise maintaining the microguidewire in position, exchanging the standard microcatheter for (1) a balloon catheter to perform balloon angioplasty of the cerebral arterial blood vessels, or (2) a stent catheter to perform stenting of the cerebral arterial blood vessels, and collecting any debris or clots that are dislodged during the balloon angioplasty and or stenting in the cerebral arterial blood vessels in the filter membrane. The methods of this invention also comprise maintaining the microguidewire in position and administering clot dissolving drugs or thrombolytics to a patient in need thereof through a standard microcatheter, such that any debris or clots that are dislodged will be collected by the filter membrane. The methods of this invention may comprise additional steps, e.g., recovering the distal embolic protection device by advancing a standard microcatheter, balloon catheter, or stent catheter over the variable thickness microguidewire, and withdrawing the distal embolic protection device and the standard microcatheter, balloon catheter or stent catheter.
Various embodiments of the present invention are shown in the figures and described in detail below.
The left common carotid artery 45 divides into the left external carotid artery 55 and the left cervical internal carotid artery 50 in the neck. The left internal carotid artery in the cervical or neck portion 50 enters the base of skull and continues as the petrous portion of the left internal carotid artery 180. The petrous portion of the left internal carotid artery 180 then continues as the tortuous cavernous portion of the left internal carotid artery 175. The left internal carotid artery then pierces the dura or covering layering of the brain to form the supraclinoid portion of the left internal carotid artery 165 and gives off the left posterior communicating artery 170 which helps form the circle of Willis or the collateral pathway to other blood vessels in the brain. The supraclinoid portion of the left internal carotid artery 165 then bifurcates 145 into the left middle cerebral artery 150 as well as the left anterior cerebral artery 140 at the left internal carotid artery bifurcation 145. The left middle cerebral artery divides into several branches and the main ones being the left middle cerebral artery superior division 155 and the left middle cerebral artery inferior division 160. The A1 segment of the left anterior cerebral artery 140 further continues as the A2 segment of the left anterior cerebral artery 135 and at the junction of the A1 and A2 segments gives off an important branch called the anterior communicating artery 130 that communicates with the blood vessels from the right side of the brain to also form the circle of Willis.
In this invention, the internal carotid arteries from the petrous, cavernous and supraclinoid portions and their branches, along with the middle cerebral and anterior cerebral arteries and their branches are considered as cerebral arterial blood vessels (80 to 180).
In this invention, the vertebral arteries from the V2, V3, and V4 segments and their branches, along with the basilar artery and the bilateral posterior cerebral arteries and their branches are also considered as cerebral arterial blood vessels (185 to 265).
Various components of the variable thickness microguidewire may be made up of materials that are biocompatible or surface treated to produce biocompatibility. Suitable materials include e.g., stainless steel, platinum, titanium and its alloys including nickel-titanium, etc. Suitable materials also include a combination of metals and alloys such that the core of the microguidewire 334 forming the thinner segment 360 could be made from metals or alloys such as stainless steel or nickel-titanium etc. In order to provide a shapeable tip that has some trackability, and that has the capacity to retain a curved shape to avoid small vessel perforation, as well as be visible during neurovascular interventional procedures, the distal end of the core microguidewire 334 is preferably covered by a coating of a radio-opaque material or metal or alloy, e.g., platinum. To provide more support to the core microguidewire to be able to advance the microguidewire along with the filtering device through a microcatheter, the core microguidewire 334 may have a coating or covering layer, e.g., a flexible hypotube, and made of metals or alloys, e.g., nickel, titanium, platinum, tungsten etc. In the areas where the microguidewire needs to be visible namely the parts of the distal segment of the microguidewire 335 e.g. distal 30 cm and the distal tip of the microguidewire 365 including the two stops 340 and 375, the coating or covering layer over the core microguidewire, or the flexible hypotube, or the core microguidewire itself, comprise or are coated with radio-opaque materials, metals or alloys, including but not limited to platinum, tantalum, gold, palladium, tungsten, tin, silver, titanium, nickel, zirconium, rhenium, bismuth, molybdenum, or combinations of the above etc to enable visibility during neurovascular interventional procedures.
The filtering device of the distal embolic protection device of this invention may comprise a filter membrane and an expansion assembly capable of assuming an expanded configuration and a collapsed configuration. Preferably the expansion assembly comprises a plurality of struts (400, 405, 410) that connect the proximal attachment point 345 to the distal attachment point 355. The filter membrane may be attached to the struts and the distal attachment point, and in the expanded configuration the filter membrane has a hemispherical shape covering the struts.
The struts comprise a biocompatible material or materials that are surface treated for biocompatibility. The materials are preferably self-expanding. Suitable materials include but are not limited to stainless steel, titanium and its alloys, cobalt-chromium alloy, carbon fiber and its composites, and various biomedical polymers, e.g., polyurethane, polyethylene, polyester, polypropylene, poly tetra fluoro-ethylene, polyamides, polycarbonate or polyethylene-terephthalate. A shape memory or super-elastic material such as nickel-titanium alloy is also suitable. The number of struts will depend on the size of expansion needed for the diameter of the cerebral blood vessel. The distal embolic protection device will be suitable for use in cerebral blood vessels from vessel diameters of 1.5 mm to 4.5 mm.
In addition to the two stops in the microguidewire 340 and 375, as well as the two mobile attachment points in the filtering device 345 and 355, various portions of the distal embolic protection device including parts of the struts 400 to 410, or parts of the filter membrane 415 may be radio-opaque. Radio-opaque materials are understood as materials that are visible on a fluoroscopy screen during neurovascular interventional procedures. This allows the operator to determine the location of the device during neurovascular interventions. Radio-opaque materials include, e.g., metals or alloys including but are not limited to platinum, tantalum, gold, palladium, tungsten, tin, silver, titanium, nickel, zirconium, rhenium, bismuth, molybdenum, or combinations of the above etc. The struts may comprise metals or alloys that are radio-opaque, e.g., platinum or the others listed above. Alternatively the struts may comprise shape-elastic alloys such as nickel-titanium, which are not significantly radio-opaque but small portions of radio-opaque metals or alloys, e.g., tantalum, can be attached to non-radio-opaque struts by suturing the filter membrane to the struts with tantalum wires or other suitable radio-opaque material.
The filtering device also comprises a filter membrane 415 for collecting emboli or debris that might be released during the neurovascular intervention. The filter membrane may comprise a biomedical polymer, e.g., polyurethane (BioSpan™ made by Polymer Technology Group and Chronoflex™ made by CardioTech International), polyethylene (Rexell™ made by Huntsman), polypropylene (Inspire™ made by Dow), polyester (Hytril™ made by Dupont), poly tetra fluoro-ethylene (Teflon™ made by Dupont), polyamides (Durethan™ made by Bayer), polycarbonate (Corethane™ made by Corvita Corp), or polyethylene-terephthalate (Dacron™ made by Dupont). The filter membrane may further comprise a radio-opaque material, e.g., particles of tantalum, particles of gold, other radio-opaque agents, e.g., barium sulfate, tungsten powder, bismuth subcarbonate, bismuth oxychloride, iodine containing agents such as iohexol (Omnipaque™ made by Amersham Health). The filter membrane comprises pores 420 that are of the dimensions small enough to trap emboli or debris but large enough to allow the free passage of blood and its components such as blood cells preferably the pores are of 50 microns to 150 microns. The arrows 425 indicate the direction of blood flow within the blood vessel.
The microguidewire is thinner between the two radio-opaque stops 340 and 375 and in this thin segment 360, the microguidewire thickness is no more than about 0.010 inch (0.254 mm). This is to allow for the thickness of the filtering device comprising the struts such that in its non-expanded state the distal embolic protection device overall is no more than about 0.017 inch (0.432 mm). This is to enable the distal embolic protection device to be delivered through standard microcatheters that are commercially available (such as Echelon™ microcatheter, ev3 Inc; Excelsior™ microcatheter, Boston Scientific Corp; Prowler™ microcatheter, Cordis Neurovascular etc) that have an internal diameter of around 0.017 inch (0.432 mm).
The struts, preferably made of a biocompatible material or a material that is surface treated to be biocompatible and preferably made of a self-expanding material, are detailed in the embodiment described in
In addition to the two stops in the microguidewire 340 and 375, as well as the two mobile attachment points in the filtering device 455 and 460, various portions of the distal embolic protection devices of this invention including parts of the struts 505 and 510, or parts of the filter membrane 480 may be radio-opaque. Radio-opaque materials are understood to be materials that are visible on a fluoroscopy screen during neurovascular interventional procedures. This allows the operator to determine the location of the device during neurovascular interventions. Radio-opaque materials include metals or alloys including but are not limited to platinum, tantalum, gold, palladium, tungsten, tin, silver, titanium, nickel, zirconium, rhenium, bismuth, molybdenum, or combinations of the above. The struts can be made of metals or alloys that are radio-opaque, e.g., platinum or the others listed above. Alternatively the struts are made of shape-elastic alloys such as nickel-titanium, which are not significantly radio-opaque, and may further comprise small portions of radio-opaque metals or alloys such as tantalum, that can be attached to the non-radio-opaque struts by suturing the filter membrane to the struts with a radio-opaque material, e.g. tantalum wires etc.
The filtering device comprises a filter membrane 480 to capture emboli or debris that might be released during the neurovascular intervention. The filter membrane is preferably a biomedical polymer, e.g., polyurethane (BioSpan™ made by Polymer Technology Group and Chronoflex™ made by CardioTech International), polyethylene (Rexell™ made by Huntsman), polypropylene (Inspire™ made by Dow), polyester (Hytril™ made by Dupont), poly tetra fluoro-ethylene (Teflon™ made by Dupont), polyamides (Durethan™ made by Bayer), polycarbonate (Corethane™ made by Corvita Corp), or polyethylene-terephthalate (Dacron™ made by Dupont). The filter membrane may further comprise a radio-opaque material, e.g., particles of tantalum, particles of gold, other radio-opaque agents such as barium sulfate, tungsten powder, bismuth subcarbonate, bismuth oxychloride, iodine containing agents such as Omnipaque™. The filter has pores 485 that are small enough to trap emboli or debris but large enough to allow the free passage of blood and its components such as blood cells, preferably the pores are 50 microns to 150 microns in diameter. The arrows 500 indicate the direction of blood flow within the cerebral blood vessel.
The microguidewire is thinner between the two radio-opaque stops 340 and 375 and in this thinner segment 360, the microguidewire thickness is no more than about 0.010 inch (0.254 mm). This is to accommodate the filtering device such that in its non-expanded configuration the thickness of the filtering device is less than or equal to 0.017 inch (0.432 mm). This is to enable the distal embolic protection device to be delivered through standard microcatheters that are commercially available (such as Echelon™ microcatheter, ev3 Inc; Excelsior™ microcatheter, Boston Scientific Corp; Prowler™ microcatheter, Cordis Neurovascular etc) that have an internal diameter of about 0.017 inch (0.432 mm).
The ring, and if present the plurality of struts, are made of biocompatible materials or materials that are surface treated such that they are biocompatible. The materials are preferably self-expanding as described in
In addition to the two stops in the microguidewire 340 and 375, as well as the two mobile attachment points in the device 535 and 530, various portions of the distal embolic protection device including the ring 525, or parts of the filter membrane 555 may further comprise a radio-opaque material. Radio-opaque materials are understood as materials that are visible on a fluoroscopy screen during neurovascular interventional procedures. This allows the operator to determine the location of the device during neurovascular interventions. Radio-opaque materials can include metals or alloys, including but not limited to platinum, tantalum, gold, palladium, tungsten, tin, silver, titanium, nickel, zirconium, rhenium, bismuth, molybdenum, or combinations of the above etc. The struts can be made up of metals or alloys that are radio-opaque such as platinum or the others listed above. Alternatively the struts may be made of shape-elastic alloys such as nickel-titanium, which are not significantly radio-opaque, but may be made radio-opaque by attaching small portions of radio-opaque metals or alloys, e.g., tantalum, to the non-radio-opaque struts by suturing the filter membrane to the struts with a radio-opaque material, e.g., tantalum wires etc.
The filtering device comprises a filter membrane 555 that extends from the ring 525 to the distal attachment point 530 and acts as a filter for emboli or debris that might be released during the neurovascular intervention. The filter membrane may cover the struts. Materials for this filter include but are not limited to biomedical polymers such as, e.g., polyurethane (BioSpan™ made by Polymer Technology Group and Chronoflex™ made by CardioTech International, polyethylene (Rexell™ made by Huntsman), polypropylene (Inspire™ made by Dow), polyester (Hytril™ made by Dupont), poly tetra fluoro-ethylene (Teflon™ made by Dupont), polyamides (Durethan™ made by Bayer), polycarbonate (Corethane™ made by Corvita Corp), or polyethylene-terephthalate (Dacron™ made by Dupont). The filter has pores 560 that are small enough to trap emboli or debris but large enough to allow the free passage of blood and its components such as blood cells. Preferably the pores are 50 microns to 150 microns. The arrows 575 indicate the direction of blood flow with the cerebral blood vessel. The filter membrane may further comprise radio-opaque materials, e.g., as particles of tantalum, particles of gold, other radio-opaque agents, e.g., barium sulfate, tungsten powder, bismuth subcarbonate, bismuth oxychloride, iodine containing agents such as Omnipaque™.
The microguidewire is thinner between the two radio-opaque stops 340 and 375 and in this thinner segment 360, the microguidewire thickness is no more than about 0.010 inch (0.254 mm). This is to allow for the thickness of the distal embolic protection device, the ring and the struts if present such that in the non-expanded state the ring of the distal embolic protection device is no more than about 0.017 inch (0.432 mm). This is to enable the distal embolic protection device to be delivered through standard microcatheters that are commercially available (such as Echelon™ microcatheter, ev3 Inc; Excelsior™ microcatheter, Boston Scientific Corp; Prowler™ microcatheter, Cordis Neurovascular etc) that have an internal diameter of about 0.017 inch (0.432 mm).
While the invention is susceptible to various modifications, and alternative forms, specific examples thereof have been shown in the drawings and are herein described in detail. It should be understood, however, that the invention is not to be limited to the particular forms or methods disclosed, but to the contrary, the invention is to cover all modifications, equivalents and alternatives falling within the spirit and scope of the appended claims.
CITED REFERENCES
- 1. Sarti C, Rastenyte D, Cepaitis Z, Tuomilehto J. International trends in mortality from stroke, 1968 to 1994. Stroke. 2000; 31:1588-1601.
- 2. Wolf P A, D'Agostino R B. Epidemiology of Stroke. In: Barnett H J M, Mohr J P, Stein B M, Yatsu F, eds. Stroke: Pathophysiology, Diagnosis, and Management. 3rd ed. New York, N.Y.: Churchill Livingstone; 1998:6-7
- 3. Adams H P, Jr., Adams R J, Brott T, del Zoppo G J, Furlan A, Goldstein L B, Grubb R L, Higashida R, Kidwell C, Kwiatkowski T G, Marler J R, Hademenos G J. Guidelines for the early management of patients with ischemic stroke: A scientific statement from the Stroke Council of the American Stroke Association. Stroke. 2003; 34:1056-1083.
- 4. Rymer M M, Thrutchley D E. Organizing regional networks to increase acute stroke intervention. Neurol Res. 2005; 27:S9-16.
- 5. Furlan A, Higashida R, Wechsler L, Gent M, Rowley H, Kase C, Pessin M, Ahuja A, Callahan F, Clark W M, Silver F, Rivera F. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. Jama. 1999; 282:2003-2011.
- 6. Yadav J S. Carotid stenting in high-risk patients: design and rationale of the SAPPHIRE trial. Cleve Clin J Med. 2004; 71 Suppl 1:S45-46.
- 7. Bose A, Hartmann M, Henkes H, Liu H M, Teng M M, Szikora I, Berlis A, Reul J, Yu S C, Forsting M, Lui M, Lim W, Sit S P. A novel, self-expanding, nitinol stent in medically refractory intracranial atherosclerotic stenoses: the Wingspan study. Stroke. 2007; 38:1531-1537. Epub 207 March 1529.
Claims
1. (canceled)
2. A method of treating vasculature, the method comprising:
- tracking a treatment device through a catheter from a proximal end of the catheter to a distal end of the catheter, the treatment device comprising: an elongate element comprising: a proximal segment including a proximal hypotube around a first portion of core, a distal segment including a distal hypotube around a second portion of the core, and a third segment comprising a third portion of the core, the third segment longitudinally between the proximal segment and the distal segment, and a treatment tool around the third segment; and
- deploying the treatment tool out of the catheter.
3. The method of claim 2, wherein the treatment tool comprises a balloon.
4. The method of claim 2, wherein the treatment tool comprises a stent.
5. The method of claim 2, wherein the treatment tool comprises a filtering device.
6. The method of claim 5, comprising collecting thrombo-embolic material.
7. The method of claim 6, further comprising at least one of performing an angioplasty procedure and positioning a stent, wherein the at least one of performing the angioplasty procedure and positioning the stent dislodges the thrombo-embolic material.
8. The method of claim 6, further comprising:
- advancing a guidewire across the thrombo-embolic material;
- tracking the catheter over the guidewire and across the thrombo-embolic material; and
- before tracking the device through the catheter, withdrawing the guidewire from the catheter.
9. A vascular treatment system comprising:
- a core;
- a first hypotube around a first portion of the core;
- a second hypotube around a second portion of the core;
- a third hypotube around a third portion of the core, the third hypotube longitudinally between the first hypotube and the second hypotube, the third hypotube transformable between a collapsed configuration and an expanded configuration, the third hypotube comprising: a proximal attachment point, a distal attachment point, the third hypotube rotatable around the third portion of the core, and a plurality of struts connecting the proximal attachment point and the distal attachment point, the third hypotube longitudinally movable along the third portion of the core in the expanded configuration; and
- a filter membrane coupled to the third hypotube.
10. The system of claim 9, wherein, when the third hypotube is in the expanded configuration, the filter membrane has a hemispherical, helical, or conical shape.
11. The system of claim 9, wherein the catheter comprises a balloon catheter.
12. A vascular treatment system comprising:
- a treatment device comprising: a proximal hypotube around a first portion of a core; a distal hypotube around a second portion of the core, the distal hypotube longitudinally spaced from the proximal hypotube by a segment comprising a third portion of the core; a treatment tool in a collapsed configuration around the segment and between the proximal hypotube and the distal hypotube, the treatment tool transformable between the collapsed configuration and an expanded configuration.
13. The system of claim 12, wherein the treatment tool comprises a balloon.
14. The system of claim 12, wherein the treatment tool comprises a stent.
15. The system of claim 12, wherein the treatment tool comprises a filtering device.
16. The system of claim 15, wherein the filtering device comprises:
- a proximal attachment point;
- a distal attachment point;
- a plurality of struts connecting the proximal attachment point and the distal attachment point, the struts configured to self-expand from the collapsed configuration to an expanded configuration; and
- a filter membrane coupled to the at least one of the struts and the distal attachment point,
- wherein the filtering device is rotationally and longitudinally movable relative to the core.
17. The system of claim 12, further comprising a catheter.
18. The system of claim 17, wherein the treatment tool is trackable uncovered through the catheter from a proximal end of the catheter to a distal end of the catheter.
19. The system of claim 17, wherein the catheter comprises a balloon catheter.
20. The system of claim 17, wherein the catheter comprises a stent catheter.
21. The system of claim 17, wherein the catheter has an inner diameter that is no more than 0.017 inches.
Type: Application
Filed: May 12, 2015
Publication Date: Aug 27, 2015
Inventor: Vikram Janardhan (Sacramento, CA)
Application Number: 14/709,794